Please try another search
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Name | Age | Since | Title |
---|---|---|---|
Katsuto Tamai | - | - | Director |
Yoichiro Shimada | - | - | External Audit & Supervisory Board Member |
Akihiro Mizukami | 67 | - | External Audit & Supervisory Board Member |
Yoji Kudo | - | - | Full-Time External Audit & Supervisory Board Member |
Noriko Sawai | - | 2019 | Independent Outside Director |
Masatsune Okajima | 55 | 2019 | President, CEO & Representative Director |
Tadahiro Nagai | - | 2020 | Independent Outside Director |
Kensuke Tomita | 74 | 2013 | Executive Chairman |
Katsuto Tamai | - | 2022 | Chief Scientific Officer, Director of Basic Research Department & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review